Odds ratio from logistic regression model adjusted for age, age of onset, body mass index, and sex.
A cross-sectional study of psoriasis triggers among different ethno-racial groups
To the Editor: Psoriasis is a common inflammatory skin condition that affects 1.5% to 3% of the US population. 1 Although the prevalence and genetic risk factors of psoriasis differ by ethnicity, 1, 2 it is unknown how exacerbating factors of psoriasis compare across ethno-racial groups. The genetic risk factors specific to ethno-racial groups may predispose individuals to variations in skin responses when exposed to certain environmental insults. The aim of this study was to identify whether exacerbating factors for psoriasis vary between ethno-racial groups.
We used cross-sectional survey data from 897 adult and pediatric patients with psoriasis seen from 2006 to 2016 at the University of CaliforniaeSan Francisco Department of Dermatology. Patients were classified into 4 ethno-racial groups (61% self-identified as white, 25% as Asian, 8% as Hispanic/Latino, and 5% as ''other''). To compare the distribution of 6 common patient-reported exacerbating factors (stress, infection, skin injury, strep throat, winter season, medications) between ethno-racial groups, we conducted multivariable logistic and analysis of covariance regression analyses in R, with the use of body mass index, age, age of onset, and sex as covariates. The Fisher's exact test was used to compare the distribution of medication types.
Analysis of baseline demographics revealed that Asians were significantly younger at the time of presentation than were whites. Hispanics/Latinos had higher body mass index values than did whites. Age of onset and sex distribution did not differ significantly between ethno-racial groups. Logistic regression models (Table I) revealed that Asians had more than twice the odds of reporting stress as an exacerbating factor compared with that reported by whites (odds ratio, 2.05 [95% CI, 1.18-3.70], P ¼ .0135). Similarly, there was a trend among Hispanics/Latinos toward high odds of reporting stress as an exacerbating factor compared with that reported by whites (odds ratio, 2.27; P ¼ .073). There was also a trend toward lower odds of medications as an exacerbating factor among Asians compared with that in whites (odds ratio, 0.137; P ¼ .056). Among the 47 respondents who listed medication as an exacerbating factor, the most commonly reported offenders were topical/systemic corticosteroids (23.4%), beta-blockers/other anti-hypertensives (17.0%), and antibiotics/antifungals (10.6%). Interestingly, 7 of the 8 subjects who reported betablockers/anti-hypertensives as exacerbating factors were white, although the distribution was not significantly different from non-whites (P ¼ .1605). Supplemental analyses with the use of an analysis of covariance model showed similar results (Supplemental Table I ; available at http://www. jaad.org).
These findings suggest that environmental factors such as stress and medication may play different roles in exacerbating psoriasis in different ethno-racial groups. The higher frequency of stress as an exacerbating factor in Asians could reflect biologic differences in response to stress 3 or a higher perception of stress among Asians. Medication side effects may be ethnicity-dependent, as observed with differences caused by human leukocyte antigen alleles. 4 Limitations of our study include the exclusion of the ''other'' ethnic group because of the small sample size. Pediatric and adult patients could not be directly compared because of the small number of pediatric patients in our cohort. The role of medication as an exacerbating factor versus the disease for which it was being used is difficult to determine. Despite these limitations, our findings Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: Reassurance to patients but more data are needed
To the Editor: For young patients suffering from atopic dermatitis, plaque psoriasis, and alopecia areata, new targeted therapies offer significant promise. The majority of these conditions present in individuals of reproductive age. 1 Thus, there is a need to understand how new systemic drugs affect future fertility. In oncology, adverse effect on fertility is an important consideration for treatment selection. In dermatology, established systemic medications such as methotrexate and cyclosporine have known fertility risks, including impaired spermatogenesis and sperm motility in humans. 1, 2 We conducted a retrospective review of US, EU, and Canadian regulatory data and a literature search to assess the fertility risk of medications approved after 2004. Recent off-label drugs were also included. We classified medications by using a previously published A/B/C/D/X/N fertility risk scheme analogous to the US Food and Drug Administration's former pregnancy risk system. 3 For females, 25% of medications (3 of 12) showed fertility risk in animals (category C). In mice, apremilast caused prolonged estrous cycles and increased early postimplantation losses at 1.8 times the maximum recommended human dose (MRHD) (see Table I ). Given the key role of cyclic adenosine monophosphate in egg maturation, the inhibition of phosphodiesterase 4, which degrades cyclic adenosine monophosphate, could adversely affect fertility. 4 The janus kinase inhibitors (tofacitinib, ruxolitinib) resulted in increased postimplantation losses in mice. Higher doses of tofacitinib resulted in decreased pregnancy rate, corpora lutea, implantation sites, and viable fetuses. Mechanistically, janus kinase signaling plays a critical role in neuroendocrine control of female reproduction in mice. 5 Animal studies in 58% of medications (7 of 12) did not show ovarian toxicity (category B) with testing done at 8 to 50 times the MRHD. Finally, 17% (2 of 12) had an unknown risk (category N). No human data for females were available for any of the medications.
In males, all medications received a category B rating. Ten of the 12 systemic medications (83%) did not show sperm toxicity in animal studies conducted in mice, rats, or monkeys (Table I) . Adalimumab and etanercept lacked animal data, but the limited available human data did not reveal gonadal toxicity (category B). 2 The impact of new systemic medications for common dermatologic conditions on future fertility is largely unknown, but the available data suggest that most treatments have no adverse effects. Because biologics are designed as antibodies targeted toward human cytokines and receptors, the ability to conduct and interpret animal safety studies presents a challenge. A lack of adverse effects on animal fertility does not exclude an adverse impact on human gametes or reproduction. 2, 3 The wide variation in MRHD exposure suggests a need for greater regulatory harmony for preclinical fertility testing in animals, which remains the primary source of information on potential human fertility risk. Ultimately, 
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